



LYMPHOCLONAL™

Ref: CYT-LC



For In Vitro Diagnostic use

INTENDED USE

LYMPHOCLONAL™ is a four-color direct immunofluorescence reagent for use in flow cytometry designed to simultaneously determine in peripheral blood, bone marrow and other body fluids the major lymphocyte subpopulations, including the total number of T lymphocytes (CD3+), B lymphocytes (CD19+) and natural killer cells (CD3-CD56+) as well as helper/inducer (CD3+CD4+) and suppressor/cytotoxic (CD3+CD8+) T lymphocyte subsets, B lymphocytes with immunoglobulins bearing kappa light chains (CD19+ Igκ+), and B lymphocytes with immunoglobulins bearing lambda light chains (CD19+ Igλ+).

SUMMARY AND EXPLANATION

Flow Cytometry is a powerful tool for the analytical and quantitative characterization of cells which provides rapid, quantitative and multiparametric analysis of heterogeneous cell populations on a cell-by-cell basis. Flow cytometry is performed on cells in liquid suspension that have been incubated with fluorescently-labeled antibodies directed against specific cellular proteins. The relative fluorescence intensity of the positive cells indicates the amount of antibody bound to specific binding sites on the cells, and therefore provides a relative measure of antigen expression.

Human lymphocytes may be classified in three main populations according to their biological function and their cell surface antigen expression: T lymphocytes, B lymphocytes and natural killer (NK) cells. T lymphocytes (CD3+), the precursors of which originate in the bone marrow and then migrate and mature in the thymus, can be subdivided as well in functionally different populations. The most clearly defined of these are helper/inducer T cells (CD3+CD4+) and suppressor/cytotoxic T cells (CD3+CD8+). T cells produce no antibodies and are the mediators of cell immunity. B lymphocytes (CD19+) are the producers of antibodies, they mediate humoral immunity particularly effective against toxins, whole bacteria, and free viruses. NK cells (CD3-CD56+) mediate cytotoxicity against certain tumors and virus-infected cells. NK-mediated cytotoxicity does not require class I or class II major histocompatibility complex (MHC) molecules to be present on the target cell.

LYMPHOCLONAL™ recognizes the antigens CD3, CD19, CD56, CD4, CD8, kappa light chains and lambda light chains present in the different lymphocyte subsets, and can therefore be used in the characterization studies for immunophenotyping of lymphocytes. These studies are widely applied for monitoring of the immunologic status of post-transplant patients and in the characterization and follow-up of immunodeficiencies, autoimmune diseases, leukemia etc⁽¹⁻³⁾.

PRINCIPLES OF THE PROCEDURE

Flow cytometry (FC) is an innovative technology by means of which different cell characteristics are simultaneously analyzed on a single cell basis. This is achieved by means of hydrodynamic focusing of cells that pass aligned one by one in front of a set of light detectors; at the same time they are illuminated by a laser beam. The interaction of the cells with the laser beam generates signals of two different kinds: those generated by dispersed light (FSC/SSC), which mainly reflects the size of the cell and its internal complexity, and those related to the emission of light by the fluorochromes present in the cell. These signals become electric impulses which are amplified and registered as digital signals to be processed by a computer.

When the reagent is added to the sample, the mixture of fluorochrome-labelled antibodies present in the reagent bind specifically to the antigens they are directed against, allowing the detection by FC of the different lymphoid subsets.

The erythrocyte population, which could hinder the detection of the target population, is eliminated by the use of a red blood cell lysing solution previous to acquire the sample on the cytometer. The use of Quicklysis™ (CYT-QL-1) erythrocyte lysing solution is recommended, since it requires no further washing step and contains no fixative, therefore minimizing the handling of the sample and avoiding the cell loss associated to the centrifuge process.^(4, 5)

The different lymphocyte subsets count is generally expressed as the number of positive cells per microliter of sample (absolute counts), or as the percentage of positive cells per lymphocytes or leucocytes present in the sample which can itself be determined by FC based on its typical pattern of FSC/SSC (size/granularity or complexity). Because each flow cytometer has different operating characteristics each laboratory must determine its optimal operating procedure.

REAGENT COMPOSITION

LYMPHOCLONAL™ is provided in phosphate buffered saline with 0.1% sodium azide. It contains:

- Purified monoclonal CD8 antibody conjugated with fluorescein isothiocyanate (FITC), clone: UCH-T4 , isotype: IgG2a
- Purified polyclonal antibody anti-lambda light chains conjugated with fluorescein isothiocyanate (FITC).
- Purified monoclonal CD56 antibody conjugated with R-phycoerythrin (PE), clone: C5.9, isotype: IgG2b
- Purified polyclonal antibody anti-kappa light chains conjugated with R-phycoerythrin (PE).
- Purified monoclonal CD19 antibody conjugated with the peridin chlorophyll protein-Cyanine 5.5 tandem (PerCP-Cy5.5), clone: SJ25C1, isotype: IgG1
- Purified monoclonal CD4 antibody conjugated with the peridin chlorophyll protein-Cyanine 5.5 tandem (PerCP-Cy5.5), clone: SK3 , isotype: IgG1
- Purified monoclonal CD3 antibody conjugated with allophycocyanin (APC), clone: SK7, isotype: IgG1

Purification: Affinity chromatography

Amount per 0.5 ml vial: 20 tests (25 µl LYMPHOCLONAL™ to 10⁶ cells)

Reagents are not considered sterile.

STORAGE CONDITIONS

The reagent is stable until the expiration date shown on the label, when stored at 2-8° C. The reagent should not be frozen or exposed to direct light during storage or during incubation with cells. Keep the reagent vial dry. Once opened, the vial must be stored in a vertical position to avoid any possible spillage.

WARNINGS AND RECOMMENDATIONS

1. For in vitro diagnostic use.
2. This product is supplied ready to use. If it is altered by dilution or addition of other components, it will be invalidated for in vitro diagnostic use.

3. The reagent is stable until the expiration date shown on the label if it is properly stored. Do not use after the expiration date shown on the label. If the reagents are stored in conditions different from those recommended, such conditions must be validated by the user.
4. Alteration in the appearance of the reagent, such as the precipitation or discoloration indicates instability or deterioration. In such cases, the reagent should not be used.
5. It contains 0.1% sodium azide (CAS-Nr. 26628-22-8) as a preservative, but even so care should be taken to avoid microbial contamination of reagent or incorrect results may occur.
 - Sodium azide (NaN_3) is harmful if swallowed (R22), if swallowed, seek medical advice immediately and show this container or label (S46).
 - Wear suitable protecting clothing (S36).
 - Contact with acids liberates very toxic gas (R32).
 - Azide compounds should be flushed with large volumes of water during disposal to avoid deposits in metal drains where explosive conditions may develop.
6. All patient specimens and materials with which they come into contact are considered biohazards and should be handled as if capable of transmitting infection⁽⁶⁾, and disposed according to the legal precautions established for this type of product. Also recommended is handling of the product with appropriate protective gloves and clothing, and its use by personnel sufficiently qualified for the procedures described. Avoid contact of samples with skin and mucous membranes. After contact with skin, wash immediately with plenty of water.
7. Use of the reagent with incubation times or temperatures different from those recommended may cause erroneous results. Any such changes must be validated by the user.

PROCEDURE

Material included

LYMPHOCLONAL™ is sufficient for 20 determinations (25 µl reagent to 10⁶ cells).

Material required but not included

- 488 nm ion argon laser-equipped flow cytometer and appropriate computer hardware and software.
- Test tubes suitable for obtaining samples in the flow cytometer used. Usually tubes with a rounded bottom for 6 mL, 12x 75 mm are used.
- Automatic pipette (100µL) and tips.
- Micropipette with tips.
- Chronometer
- Vortex Mixer
- Isotypic control reagent
- Quicklysis™ lysing solution
- Wash buffer as phosphate buffered saline (PBS) pH 7.4 containing 0,1% sodium azide.
- Perfect-Count Microspheres™ (CYT-PCM-50) necessary for determining absolute counts.

Preparation

The protocol to process samples with LYMPHOCLONAL™ reagent depends on the procedure of the sample:

- Whole blood sample must be taken aseptically by means of a venipuncture^(7, 8) in a sterilized tube for blood collection containing an appropriate anticoagulant (use of EDTA is recommended). The analysis requires one hundred (100) µl of the whole blood sample per tube, assuming a normal range of approximately 4 to 10 x 10³ leucocytes per µl. For samples with a high white blood cell count, dilute samples with PBS to obtain a concentration of cells approximately equal to 1 x 10⁴ cells/µL. Store the blood samples at 18-22°C until they are to be tested. It is advisable to test blood samples within the 24 hours after their extraction. Hemolyzed samples or samples with suspended cell aggregates should be rejected.
- Bone marrow sample should be pass 3 or 4 times through a syringe in order to disaggregate cell clumps. Perform a white blood cell count of the sample and dilute samples with PBS to obtain a concentration of cells approximately equal to 1 x 10⁴ cells/µl.
- Dilution is not required for other body fluid samples such as fine needle aspiration (FNA) or cephalorraquid fluid, which contain low lymphocyte counts.

Before staining samples of peripheral blood and bone marrow, the sample must be washed to remove the soluble serum proteins (step 1). In case of lymph node aspirates, fine needle aspiration or cephalorraquid fluid samples this previous step is not needed.

1. Add 100 µL of the peripheral blood or bone marrow sample to each tube, add 3 ml of PBS pH 7.4 and centrifuge at 300 x g for 5 minutes, then aspirate the supernatant. Wash again using 3 ml of PBS pH 7.4 and centrifuge at 300 x g for 5 minutes, aspirate the supernatant, leaving approximately 100-150 µl of fluid.
2. Mix 100µl of blood or bone marrow sample with 25µl of LYMPHOCLONAL™. In case of working with other body fluids with fewer cells, such as fine needle aspirations, cephalorraquid fluid, bronchoalveolar lavage, gastric lavage, etc, mix 200µl of sample with 25µl of LYMPHOCLONAL™.

To evaluate the non-specific binding of the antibody, an appropriated isotype control tube can be prepared.

3. Incubate for 10 minutes at room temperature in the dark.
4. Add 2 ml of Quicklysis™* erythrocyte lysing solution and incubate the sample for 10 minutes at room temperature in the dark.
5. Acquire directly on the flow cytometer within the first four hours after finishing the sample preparation. If the samples are not acquired immediately after preparation, they should be stored at 2-8°C in the dark. Calibration of the instrument must be done according to the manufacturer's advice. Before acquiring samples, adjust the threshold or discriminator to minimize debris and ensure populations of interest are included. Before acquiring the sample on the flow cytometer, mix the cells on the vortex at low speed to reduce aggregation.

*Note: The use of other lysing solutions may require the elimination of the lysed red blood cells. Follow the manufacturer's recommended protocol of the lysing solution used.

If using Perfect-Count Microspheres™ for calculating absolute counts, mix the Perfect-Count Microspheres™ vial manually for 30-40 seconds (do not use Vortex) immediately prior to add to the sample. Using the reverse pipetting technique, add to each tube the same volume of Perfect-Count Microspheres™ as the one used for the sample addition (100 µl in case of blood or bone marrow sample and 200 µl in case of other body fluids sample)

Flow cytometry analysis


Check that the cytometer is correctly aligned and standardized for light dispersion (FSC/SSC on linear scale) and fluorescent intensity (FL1, FL2, FL3 FL4 on logarithmic scale) and that the right color compensation has been set following the instructions of the cytometer manufacturer.

Analysis of the LYMPHOCLONAL™ files becomes complicated with a manual definition of gates and regions, because different cell populations are present in the same fluorescence. CYTOGNOS recommends the use of the software INFINICYT. Contact CYTOGNOS or its authorized distributor about the advantages and ways to get this analysis software.

To perform a manual analysis of the results we recommend follow the template shown in the following figures. Data show representative flow cytometry data on peripheral blood (healthy individual) stained with LYMPHOCLONAL™.

1. Dot plot n° 1: FSC versus SSC, ungated. Draw a region (R1) to select the Lymphoid Area according to its typical low light scatter properties. This region defines all lymphocytes and some contaminants.

1. Gate: No gate




Gate Statistics


File: ACM5475.001			
Sample ID: ACM5475			
Patient ID:			
Gate: Lymphoid area			
Gate	Events	% Gated	% Total
Lymphoid area	3460	100.00	17.30
T-Lymphocytes	1834	53.01	9.17
G3	1626	46.99	8.13
B-Lymphocytes	245	7.08	1.23
G5	1381	39.91	6.91
NK cells	1161	33.55	5.80

2. Dot plot n° 2: FL4 (CD3-APC) versus SSC, gated on region R1. Draw a region (R2) to include all the bright CD3+ T lymphocytes, which should appear as a compact CD3+ cluster with low SSC.
3. Dot plot n° 3: FL1 (CD8-FITC + sIgλ-FITC) versus FL3 (CD4-PerCP-Cy5.5 + CD19-PerCP-Cy5.5), gated on T lymphocytes defined as R2 AND R1. Set quadrants to distinguish between the T lymphocyte subsets: CD3+CD4+CD8- (upper left: UL), CD3+CD4+CD8+ (upper right: UR), CD3+CD4-CD8- (lower left: LL), CD3+CD4-CD8+ (lower right: LR).

2. Gate: Lymphoid Area
= R1



3. Gate: T lymphocytes
= R2 AND R1




Quadrant Statistic:


File: ACM5475.001			
Sample ID: ACM547			
Patient ID:			
Gate: T-Lymphocyte:			
Quad	Events	% Gate	% Total
UL	1490	81.24	7.45
UR	66	3.60	0.33
LL	13	0.71	0.07
LR	265	14.45	1.32

4. Dot plot n° 4: FL3 (CD4-PerCP-Cy5.5 + CD19-PerCP-Cy5.5) versus SSC, gated on G3 defined as R1 AND NOT R2. Draw a region (R3) to include the CD19+ B lymphocytes, which should appear as a compact CD19+ cluster with low SSC.
5. Dot plot n° 5: FL1 (CD8-FITC + sIgλ-FITC) versus FL2 (CD56-PE + sIgκ-PE), gated on B lymphocytes defined as G3 AND R3. Set quadrants to distinguish between the B lymphocyte subsets: CD19+sIgκ+ (upper left: UL), CD19+sIgλ+ (lower right: LR).

4. Gate: G3
= R1 AND NOT R2



5. Gate: B-Lymphocytes
= G3 AND R3




Quadrant Statistic:


File: ACM5475.001			
Sample ID: ACM547			
Patient ID:			
Gate: B-Lymphocytes			
Quad	Events	% Gate	% Total
UL	149	60.82	0.74
UR	5	2.04	0.03
LL	20	8.16	0.10
LR	71	28.98	0.36

6. Dot plot n° 6: FL2 (CD56-PE + sIgκ-PE) versus SSC, gated on G5 defined as G3 AND NOT R3. Draw a region (R4) to include the NK cells, which should appear as a CD56+ cluster with low SSC.
7. Dot plot n° 7: FL1 (CD8-FITC + sIgλ-FITC) versus FL2 (CD56-PE + sIgκ-PE), gated on NK cells defined as G5 AND R4. Set quadrants to distinguish between the NK cell subsets: CD56+CD8- (upper left: UL), CD56+CD8+ (upper right: LR).

6. Gate: G5
= G3 AND NOT R3



7. Gate: NK Cells
= G5 AND R4



Quadrant Statistics:			
File: ACM5475.001			
Sample ID: ACM547			
Patient ID:			
Gate: NK cells			
Quad	Events	% Gatec	% Total
UL	581	50.04	2.90
UR	575	49.53	2.88
LL	3	0.26	0.01
LR	2	0.17	0.01

The gate list to develop this template is shown in the following figure:

Window: LYMPHOCLONAL

Multi	Hilite color	Color	Label	Definition
		Red	Lymphoid area	R1
		Pink	T-Lymphocytes	R2 AND R1
		Green	G3	R1 AND NOT R2
		Light Blue	B-Lymphocytes	G3 AND R3
		Dark Blue	G5	G3 AND NOT R3
		Blue	NK cells	G5 AND R4
		Yellow	G7	R7
		Teal	G8	R8

RESULTS

The different lymphocyte subset counts can be expressed as the percentage of positive cells per lymphocytes or leucocytes present in the sample. Estimation of total lymphocyte percentage must be calculated as the sum of the T-lymphocytes percentage (R2 AND R1) + the B lymphocytes percentage (G3 AND R3) + the NK cells percentage (G5 AND R4) to avoid the contaminants included in the lymphoid area.

The different lymphocyte subsets count can be also expressed as the number of positive cells per microliter of sample (absolute counts). Absolute counts may be determined by two methods:

- The double platform method to calculate absolute counts combines results from hematology analyzer and flow cytometry and uses the following formula:

$$\text{Absolute Counts (cells/}\mu\text{l)} = \text{Total White Blood Cell Count (cells/}\mu\text{l obtained from haematology analyzer)} \times \% \text{ lymphocytes} \times \% \text{ positively-stained cells} \div 10^4$$
- The single platform method has emerged as the method of the choice for absolute cell enumeration because comparative laboratory and external quality assessment studies have demonstrated that this methodology offers a lower intra- and inter-laboratory variation^(9, 10). Microbead-based technology consists of known amounts of fluorescent microbeads are admixed to a known volume of stained sample in a lyse-no-wash technique and the beads are counted along with cells. CYTOGNOS recommends the use of Perfect-Count Microspheres™ (CYT-PCM-50) to determine absolute counts using the following formula:

$$\text{Absolute Count (Cells/}\mu\text{l)} = \frac{\text{Total number of cells of interest counted}}{\text{Total number of Perfect-Count Microspheres™ counted}} \times \frac{\text{N}^{\circ} \text{ of Perfect-Count Microspheres /}\mu\text{l}}{\text{(value specified by manufacturer)}}$$

LIMITATIONS

- Blood samples should be stored at 18-22°C and be tested within the 24 hours after they are obtained.
- It is advisable to acquire stained samples on the cytometer as soon as possible to optimize the results. Nonviable cells may stain nonspecifically. Prolonged exposure of whole blood samples to lytic reagents may cause white cell destruction and loss of cells from the target population.
- When using whole blood procedures, all red blood cells may not lyse under following conditions: nucleated red blood cells, abnormal protein concentration or hemoglobinopathies. This may cause falsely decreased results due to unlysed red blood cells being counted as leucocytes.
- Results obtained by flow cytometry may be erroneous if the cytometer laser is misaligned or the gates are improperly set
- Each laboratory should establish a normal range for lymphocyte subsets using its own test conditions. The data for the reagent's performance have been obtained from whole blood samples collected with EDTA as anticoagulant. The reagent's performance may be affected by the use of other anticoagulants.
- Certain patients may present special problems due to altered or very low number of certain cellular population.
- Cells separated from whole blood by means of density gradients may not have the same relative concentrations of cells as unseparated blood. This may be relatively insignificant for samples from individuals with normal white blood cell counts. In leucopenic patients, the selective loss of specific subsets may affect the accuracy of the determination.
- It is important to understand the normal pattern of expression of these antigens and its relation to the expression of other relevant antigens to carry out an adequate analysis⁽¹¹⁻¹⁵⁾
- Abnormal states of health are not always represented by abnormal percentages of certain leucocyte populations. An individual who may be in an abnormal state of health may show the same leucocyte percentages as a healthy person. For this reason, it is advisable to use the test results in combination with other clinical and diagnosis data.

EXPECTED VALUES

Each laboratory must establish its own normal reference ranges for lymphocyte subsets counting, since such values may be influenced by age, sex and race⁽¹⁶⁻¹⁸⁾. The reference ranges for different lymphocyte subsets shown in the following table are expressed as the percentage of the lymphocyte subpopulations of the total lymphocyte count. These data were determined using the analysis software

CYTORAMA-LYMPHOCLONAL™ at CYTOGNOS, and correspond to peripheral blood samples from normal adult between the ages of 18 and 60 years.

LYMPHOCYTE SUBSET	MEAN	MAX VALUE	MIN VALUE
%Total T lymphocytes (CD3+)	76.01	87.40	55.83
% T lymphocytes CD4+CD8-	46.11	60.62	34.48
% T lymphocytes CD4-CD8++	23.45	34.57	10.78
% T lymphocytes CD4-CD8+	5.91	14.81	1.84
% T lymphocytes CD4+CD8+	0.51	2.76	0.06
%Total B lymphocytes (CD19+)	10.95	20.33	5.03
% B lymphocytes slgκ+	6.44	11.81	2.95
% B lymphocytes slgλ+	4.50	8.9	2.08
% NK cells (CD56+CD3-)	13.01	25	3.35

QUALITY CONTROL

- To obtain optimum results it is advisable to verify the precision of pipettes and that the cytometer is correctly calibrated.
- The fluorochromes fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), peridinin chlorophyll protein-cyanine 5.5 (PerCP-Cy5.5), allophycocyanin (APC) emit in different wavelengths but show a certain spectral overlapping which must be corrected by means of electronic compensation if combinations of different monoclonal antibodies are used conjugated with these fluorochromes. The optimum levels of compensation can be established by analysis in a dot-plot diagram of cells from healthy individuals stained with mutually exclusive monoclonal antibodies conjugated with the fluorochromes to be used in the test.
- To evaluate the non-specific binding of the reagent, an appropriated isotype control tube can be prepared.

PERFORMANCE CHARACTERISTICS

Reproducibility:

10 repeated measures from three peripheral blood samples representing high, medium and low lymphocyte counts were evaluated. In the following table are shown the mean percentage of the different lymphocyte subsets of the total lymphocytes count, the standard deviation and the coefficient of variation obtained for each of the three levels studied:

Lymphocytes level	%Total T lymphocytes (CD3+)	% T lymphocytes CD4+CD8-	% T lymphocytes CD4-CD8++	% T lymphocytes CD4-CD8+	% T lymphocytes CD4+CD8+	%Total B lymphocytes (CD19+)	% B lymphocytes slgκ+	% B lymphocytes slgλ+	% NK cells CD56+CD3-
High	85.91±0.65 (CV=0.76)	67.86±0.90 (CV=1.37)	17.20±0.18 (CV=1.04)	0.59±0.14 (CV=24.95)	0.23±0.09 (CV=41.15)	4.85±0.26 (CV=5.45)	2.87±0.21 (CV=7.34)	1.97±0.14 (CV=7.53)	9.22±0.73 (CV=7.58)
Medium	83.36±1.67 (CV=2.01)	51.84±1.41 (CV=2.72)	28.98±0.50 (CV=1.73)	1.85±0.29 (CV=15.64)	0.65±0.09 (CV=14.97)	2.43±0.39 (CV=16.36)	1.56±0.28 (CV=18.18)	0.8±0.18 (CV=23.23)	13.81±2.06 (CV=14.93)
Low	83.49±2.53 (CV=3.04)	66.86±3.57 (CV=5.34)	10.54±2.18 (CV=20.69)	5.17±1.48 (CV=28.67)	0.5±0.25 (CV=50.57)	13.32±2.28 (CV=17.18)	7.48±1.53 (CV=20.51)	5.83±0.88 (CV=15.10)	3.16±0.77 (CV=24.22)

Specificity:

The CD3 antigen is found on the cell surface of mature thymocytes and T lymphocytes in peripheral blood.

The CD4 antigen is found on a subpopulation of peripheral blood T lymphocytes, some thymocytes and some malignant cells of T-cell origin. Monocytes and macrophages show a weak expression of CD4. Normal B lymphocytes and granulocytes do not express surface CD4 antigen.

The CD8 antigen is found on a subpopulation of peripheral blood T lymphocytes, 60% of thymocytes and a limited number of malignancies of T-cell origin. Normal B lymphocytes, monocytes and granulocytes do not express surface CD8 antigen.

The CD19 antigen is found on the cell surface of normal and neoplastic B cells, being absent from T cells, monocytes and granulocytes.

Anti-Kappa Light Chains reacts with free kappa chains as well as kappa chains in intact immunoglobulin molecules.

Anti-Lambda Light Chains reacts with free lambda chains as well as lambda chains in intact immunoglobulin molecules.

The CD56 antigen is found on human peripheral blood NK cells and subsets of CD3+CD4+ and CD3+CD8+ T cells. Normal B lymphocytes, monocytes and granulocytes do not express surface CD56 antigen.

To assess cellular cross-reactivity, the CD3, CD4, CD8, CD19, CD56, anti-lambda light chains and anti-kappa light chains antibodies comprising the LYMPHOCLONAL™ were screened on normal human adult donor blood samples. Results consistently demonstrated that these antibodies react specifically with the appropriate lymphocyte populations.

Accuracy

Main lymphocyte subset percentages obtained with LYMPHOCLONAL™ were compared with results obtained with LYMPHOGRAM™ and the triple antibody combination anti-Kappa-FITC/anti-Lambda-PE/CD19-PECY5. Regression statistics reported in the following table indicate that the results are substantially equivalent in their reactivity on peripheral blood samples. Values are expressed in terms of percentage (%) of the total lymphocyte count.

Subset	%Total T lymphocytes (CD3+)	% T lymphocytes CD4+CD8-	% T lymphocytes CD4-CD8+	%Total B lymphocytes (CD19+)	% B lymphocytes slgκ+	% B lymphocytes slgλ+	% NK cells (CD56+CD3-)
R ²	0.93	0.97	0.99	0.97	0.94	0.96	0.97
Slope	0.97	1.00	1.03	1.05	0.94	0.97	1.04
Intercept	2.51	0.03	-0.28	0.33	0.25	0.15	0.11
Range	32.03-83.77	28.95-57.94	9.83-37.27	0.80-28.02	0.42-19.70	0.38-14.02	1.62-15.24
CCI	0.98	0.98	0.99	0.98	0.93	0.93	0.99


Repetitivity

The results for 10 different samples stained with 2 different lots of LYMPHOCLONAL™ were compared. Each pair of data for the same sample was analyzed, obtaining the mean fluorescence intensity (MFI) and the standard deviation from which a grouped % CV was calculated. The results of the analysis are shown in the following chart:

Subset	%Total T lymphocytes (CD3+)	% T lymphocytes CD4+CD8-	% T lymphocytes CD4-CD8+	% T lymphocytes CD4-CD8-	% T lymphocytes CD4+CD8+	%Total B lymphocytes (CD19+)	% B lymphocytes slgk+	% B lymphocytes slgl+	% NK cells (CD56+CD3-)
Mean	66.02	41.12	20.97	3.51	0.27	14.45	8.42	6.02	10.05
Grouped SD	2.88	1.15	1.45	0.44	0.05	1.20	0.72	0.62	0.83
IGrouped CV (%)	4.36	2.79	6.91	12.53	18.51	8.30	8.55	10.29	8.26

Linearity

Dilutions of a peripheral blood sample were made to check the concentration scale of stained cells obtained. The results show an excellent correlation level between the results obtained and expected based on the dilution used.










REFERENCES

- Orfao A, González de Buitrago JM La citometría de flujo en el laboratorio clínico. Sociedad española de bioquímica clínica y patología Molecular 1995.
- Stetler-Stevenson M. Flow cytometry analysis of lymphomas and lymphoproliferative disorders. Semin Hematol 2001 Apr;38(2):111-23.
- Okuno SH, Tefferi A, Hanson C, Katzmann JA, Li CY, Witzig TE. Spectrum of diseases associated with increased proportions or absolute numbers of peripheral blood natural killer cells. Br J Haematol. 93: 810-812 (1996)
- Menéndez P, et al. Comparison between a lyse-and-then-wash method and a lyse-non-wash technique for the enumeration of CD34+ hematopoietic progenitor cells. Cytometry (Comm. Clin. Cytometry) 34: 264-271 (1998)
- Gratama JW, Menéndez P, Kraan J, Orfao A. Loss of CD34+ hematopoietic progenitor cells due to washing can be reduced by the use of fixative-free erythrocyte lysing reagents. J Immunol. Methods 239: 13-23 (2000)
- Protection of Laboratory Workers from occupationally acquired infections. Second edition; approved guideline (2001). Villanova PA: National Committee for Clinical Laboratory Standards; Document M29-A2.
- Procedures for the collection of diagnostic blood specimens by venipuncture- approved standard; Fifth edition (2003). Wayne PA: National Committee for Clinical Laboratory Standards; Document H3-A5.
- Clinical applications of flow cytometry: Quality assurance and immunophenotyping of lymphocytes; approved guideline (1998). Wayne PA: National Committee for Clinical Laboratory Standards; Document H42-A.
- Mandy F, Brando B. Enumeration of absolute cell counts using immunophenotypic techniques. Current Protocols in Cytometry 6.8.1-6.8.26 (2000)
- Brando B, et al. Cytofluorometric methods for assessing absolute numbers of cells in blood. For the European Working Party on Clinical Cell Analysis (EWGCCA). Cytometry 42: 327-346 (2000)
- Bellido M, Rubiol E, Übeda J, Estivill C, López O, Manteiga R, Nomdedéu JF. Rapid and simple immunophenotypic characterization of lymphocytes using a new test. Haematologica 83: 681-685 (1998)
- Giustolisis GM, Gruszka-Westwood AM, Morilla RM, Matutes E. Lymphogram: a rapid flow cytometry method for screening patients with lymphocytosis. Haematologica 86: 1223-1224 (2001)
- Ruiz-Arguelles A, Pérez-Romano B. Immunophenotypic analysis of peripheral blood lymphocytes. Current Protocols in Cytometry 6.5.1-6.5.14 (2000)
- Fukushima PI, Thi Nguyen PK, O'Grady P, Stetler-Stevenson M. Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia. Cytometry (Communications in clinical Cytometry) 26: 243-252 (1996).
- Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. Cytometry 46: 23-7 (2001)
- Reichert et al. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 60:190-208 (1991)
- Prince HK et al. Influence of racial background on the distribution of T-cell subsets and Leu-11 positive lymphocytes in healthy blood donors. Diagn Immunol. 3: 33-39 (1985)
- Kotylo PK et al. Reference ranges for lymphocyte subsets in pediatric patients. Am J Clin Pathol 100:111-5 (1993)

WARRANTY

This product is warranted only to conform to the quantity and contents stated on the label. There are no warranties that extend beyond the description on the label of the product. Cytognos's sole liability is limited to either replacement of the product or refund of the purchase price.

EXPLANATION OF SYMBOLS

	Use by (use by YYYY-MM)
	Storage temperature limitation
	Consult instruction for use
	In vitro diagnostic medical device
	Batch code
	Code number
	Manufacturer

PRODUCED BY

CYTOGNOS SL

Polígono La Serna, Nave 9
37900 Santa Marta de Tormes
Salamanca (España)

Phone: + 34-923-125067

Fax: + 34-923-125128

Ordering information: admin@cytognos.com

Technical information: support@cytognos.com

www.cytognos.com

104485ENG

Last revision: ORAN 26/07/2010